Reactivation of hepatitis B virus following rituximab-plus-steroid combination chemotherapy.
about
Hepatitis B Reactivation with Novel Agents in Non-Hodgkin's Lymphoma and Prevention StrategiesMonoclonal antibody therapy and renal transplantation: focus on adverse effectsManagement of chronic hepatitis B: Canadian Association for the Study of the Liver consensus guidelinesOccult infection with hepatitis C virus: friend or foe?Efficacy of lamivudine or entecavir on acute exacerbation of chronic hepatitis B.High Risk of Hepatitis B Reactivation among Patients with Acute Myeloid LeukemiaHepatitis B reactivation in a patient with rheumatoid arthritis with antibodies to hepatitis B surface antigen treated with rituximab.Cytomegalovirus reactivation following chemoradiation for invasive cervical carcinoma.Outcome prediction of diffuse large B-cell lymphomas associated with hepatitis C virus infection: a study on behalf of the Fondazione Italiana LinfomiPrevention of hepatitis B virus reactivation in immunosuppressive therapy or chemotherapy.Reactivation of hepatitis viruses following immunomodulating systemic chemotherapy.Hepatitis B virus reactivation in patients with hepatocellular carcinoma undergoing anti-cancer therapy.Risk and prophylaxis strategy of hepatitis B virus reactivation in patients with lymphoma undergoing chemotherapy with or without rituximab.Randomized prospective study evaluating tenofovir disoproxil fumarate prophylaxis against hepatitis B virus reactivation in anti-HBc-positive patients with rituximab-based regimens to treat hematologic malignancies: The Preblin study.Analysis of HBsAg using high-sensitivity HBsAg assays in hepatitis B virus carriers in whom HBsAg seroclearance was confirmed by conventional assays.Comparative effectiveness of nucleos(t)ide analogues in chronic hepatitis B patients undergoing cytotoxic chemotherapy.Stopping Preemptive Antiviral Therapy for Hepatitis B Virus Can Be Considered for Patients with Favorable Predictors.Risk factors and outcomes of hepatitis B virus reactivation in hepatitis B surface antigen negative patients with hematological malignancies.Reactivation of hepatitis B virus (HBV) infection in adult T-cell leukemia-lymphoma patients with resolved HBV infection following systemic chemotherapy.Immunobiology of hepatitis B virus infection.Death from Liver Failure despite Lamivudine Prophylaxis during R-CHOP Chemotherapy due to Rapid Emergence M204 Mutations.Lymphocyte/monocyte ratio and cycles of rituximab-containing therapy are risk factors for hepatitis B virus reactivation in patients with diffuse large B-cell lymphoma and resolved hepatitis B.Hepatitis B virus infection correlates with poor prognosis of extranodal natural killer/T cell lymphoma.Reactivation of hepatitis B virus in rheumatoid arthritis patients treated with biological disease-modifying antirheumatic drugs.Computerized physician order entry-based system to prevent HBV reactivation in patients treated with biologic agents: the PRESCRIB project.Reactivation of hepatitis B virus in patients with undetectable HBsAg undergoing chemotherapy for malignant lymphoma or multiple myeloma.Immunosuppression in Patients with Chronic Hepatitis B.Occult hepatitis B: clinical viewpoint and management.Kinetics of peripheral hepatitis B virus-specific CD8+ T cells in patients with onset of viral reactivation.Reactivation of occult hepatitis B virus infection following cytotoxic lymphoma therapy in an anti-HBc negative patient.Entecavir versus lamivudine for hepatitis B prophylaxis in patients with haematological disease.Hepatitis B reactivation among 1962 patients with hematological malignancy in Taiwan.Treatment of primary membranous nephropathy: where are we now?Rituximab-induced hypogammaglobulinemia in patients with neuromyelitis optica spectrum disorders
P2860
Q26746486-D098F807-D53E-4259-95A9-751483CFC8DDQ26826880-66B89633-C619-44CE-9511-B8CC84B55140Q27000080-B10D9F53-028D-4C66-8B5C-DF330D4F4C8BQ30416187-68FCD76A-D5A5-4F42-9E1D-FE56789B67A0Q35567341-5E91E4A2-C4AE-446E-B197-2D0D20F04D67Q35606765-8E6E1D53-478B-4431-81F1-06A1E3B0C2E7Q37082428-4A3029F9-2E8C-4B36-9B06-24F02492C24EQ37379528-E13A957F-35EB-40C6-8BE5-9B4B0FBDAFA1Q37618904-161948B8-1DB3-4374-BAD0-2281BFB0AFD3Q37883147-DABAEADC-4809-4B76-AE9F-E60B322EC502Q38062943-E8050293-162B-46B6-9AB5-9BA715CC6517Q38224439-73C89A00-794E-4DFA-84C6-A858F400A02FQ38253568-20AAF7C6-A8A2-4ACA-A305-2BB69BE394D4Q40045559-3910FC23-A8E5-4B72-93CA-851A48573B82Q40051443-C4FEC6C1-6D34-41A4-82BC-9E52B5B3F7FCQ40642803-7BE391C3-89E4-49A3-843B-2A5A1789A1E9Q40691267-2A986A89-932E-4F47-8AD1-89EF0E2F7172Q41252998-8EBF5991-CB4A-4E3B-8CCF-F0063B1C501DQ41514638-13BB9CB3-DFFA-4334-B2DC-1318F6A72510Q41694097-7BF268E3-50D4-4085-A271-7B1A25E139DCQ42067124-EFC31B03-A208-40E6-9111-36802F966012Q42178052-B41690D8-D2B8-4591-A72B-D95449BDFDDBQ42200776-E6724982-197A-412B-A819-B4FBF8E3A585Q42227093-169B894E-8C36-49F3-8F23-EAE87B4B43E7Q42234350-95818302-CC42-42CC-86F5-9545D2C7F562Q42278229-185CFD9C-57E4-4F45-80E9-F51420E98296Q42764680-6E206E77-0A84-4908-B9BA-08AFE7B45272Q43223881-C536B127-2A62-49EB-854F-3D89EBF95855Q44218960-F7382D57-7932-42F7-835C-B6693B9A969FQ45352889-A6C1EE16-C725-4375-A048-824540EB8609Q46242353-80EDD03F-2098-440A-9F56-6A77588F0E60Q47178355-9FC499C6-BFD6-4A12-A6AE-149162E2AA1EQ47850601-E17634B0-2D82-4350-92A4-52146CF83A8BQ58742950-22A8C7BC-C4FD-4893-8E56-4638F3926E95
P2860
Reactivation of hepatitis B virus following rituximab-plus-steroid combination chemotherapy.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 06 October 2010
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Reactivation of hepatitis B vi ...... roid combination chemotherapy.
@en
Reactivation of hepatitis B vi ...... roid combination chemotherapy.
@nl
type
label
Reactivation of hepatitis B vi ...... roid combination chemotherapy.
@en
Reactivation of hepatitis B vi ...... roid combination chemotherapy.
@nl
prefLabel
Reactivation of hepatitis B vi ...... roid combination chemotherapy.
@en
Reactivation of hepatitis B vi ...... roid combination chemotherapy.
@nl
P2093
P2860
P1476
Reactivation of hepatitis B vi ...... roid combination chemotherapy.
@en
P2093
Masashi Mizokami
Ryuzo Ueda
Shigeru Kusumoto
Yasuhito Tanaka
P2860
P356
10.1007/S00535-010-0331-4
P577
2010-10-06T00:00:00Z